Related Experiment Videos
A one-year multicentre study of simvastatin in the treatment of hypercholesterolaemia. UK and Eire Simvastatin Study
Insights
Simvastatin effectively lowered cholesterol in hypercholesterolaemic patients, with significant reductions in total cholesterol and LDL cholesterol maintained for one year. The drug was well-tolerated in monotherapy and combination treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypercholesterolaemia poses a significant risk for cardiovascular diseases.
- Effective lipid-lowering therapies are crucial for managing cardiovascular risk.
Purpose of the Study:
- To evaluate the efficacy and tolerability of simvastatin monotherapy in hypercholesterolaemic patients.
- To assess the long-term lipid-lowering effects of simvastatin over one year.
Main Methods:
- A 1-year prospective study involving 475 hypercholesterolaemic individuals.
- Initial 3-month simvastatin monotherapy (10-40 mg daily), followed by additional lipid-lowering medication if needed.
- Monitoring of plasma lipid and lipoprotein levels, including total cholesterol, LDL cholesterol, triglycerides, and HDL cholesterol.
Main Results:
- Simvastatin monotherapy achieved significant mean reductions: total cholesterol by 31%, LDL cholesterol by 39%, triglycerides by 14%, and HDL cholesterol by 12% within 3 months.
- These lipid-lowering effects were sustained throughout the 1-year study period.
- 42.7% of patients with baseline total cholesterol of 6.5-7.8 mmol/l achieved target levels with simvastatin monotherapy alone.
- Additional hypolipidaemic medications did not significantly impact lipid levels.
Conclusions:
- Simvastatin monotherapy is effective in reducing and maintaining lower levels of total and LDL cholesterol in hypercholesterolaemic patients.
- Simvastatin demonstrates good tolerability as both a standalone treatment and in combination with other lipid-lowering agents.
- The study highlights simvastatin's role in achieving lipid management goals for hypercholesterolaemic individuals.
Abstract:
A 1-year prospective study was conducted in 475 hypercholesterolaemic men and women who received simvastatin monotherapy 10-40 mg daily for 3 months followed by additional lipid-lowering medication after this period, if necessary, to reach a target of plasma cholesterol < 5.3 mmol/l. Of these, 403 subjects completed 1 year of follow-up. By the end of the 3-month monotherapy period, the following percentage mean changes were seen (with 95% confidence intervals): total cholesterol (TC) -31% (-30 to -32%), low-density lipoprotein cholesterol -39% (-38 to -40%), triglycerides -14% (-11 to -17%) and high-density lipoprotein cholesterol +12% (+11 to +14%). These levels were maintained for the remainder of the study. When subjects with a baseline TC of 6.5-7.8 mmol/l were considered (n = 89), 42.7% achieved the target TC levels on simvastatin monotherapy alone. Additional hypolipidaemic medication had no significant impact on plasma lipid and lipoprotein levels. Simvastatin was well tolerated both as monotherapy and in combination.